Xiaojun Zhuang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5451987/publications.pdf

Version: 2024-02-01

759233 713466 21 574 12 21 h-index g-index citations papers 24 24 24 797 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 28-38.	2.8	125
2	Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome. Frontiers in Microbiology, 2018, 9, 1600.	3.5	91
3	Systematic Review and Meta-analysis: Short-Chain Fatty Acid Characterization in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1751-1763.	1.9	73
4	Peroxisome Elevation Induces Stem Cell Differentiation and Intestinal Epithelial Repair. Developmental Cell, 2020, 53, 169-184.e11.	7.0	33
5	Systematic review with metaâ€analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations. Alimentary Pharmacology and Therapeutics, 2022, 55, 266-276.	3.7	30
6	Gut Microbiota Profile in Pediatric Patients With Inflammatory Bowel Disease: A Systematic Review. Frontiers in Pediatrics, 2021, 9, 626232.	1.9	27
7	The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome. BMC Gastroenterology, 2020, 20, 73.	2.0	26
8	Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn's Disease. Inflammatory Bowel Diseases, 2020, 26, 1636-1647.	1.9	23
9	Alterations in Bile Acid Metabolism Associated With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1525-1540.	1.9	23
10	Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: a systematic review and meta-analysis. BMC Gastroenterology, 2021, 21, 14.	2.0	22
11	Increased small intestinal permeability and RNA expression profiles of mucosa from terminal ileum in patients with diarrhoea-predominant irritable bowel syndrome. Digestive and Liver Disease, 2016, 48, 880-887.	0.9	19
12	Intestinal Fibrosis and Gut Microbiota: Clues From Other Organs. Frontiers in Microbiology, 2021, 12, 694967.	3.5	17
13	Dietary inflammatory potential mediated gut microbiota and metabolite alterations in Crohn's disease: A fire-new perspective. Clinical Nutrition, 2022, 41, 1260-1271.	5.0	14
14	Gut Microbiota Profiles and Microbial-Based Therapies in Post-operative Crohn's Disease: A Systematic Review. Frontiers in Medicine, 2020, 7, 615858.	2.6	12
15	Index-Based Dietary Patterns and Inflammatory Bowel Disease: A Systematic Review of Observational Studies. Advances in Nutrition, 2021, 12, 2288-2300.	6.4	12
16	Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome. BMC Gastroenterology, 2020, 20, 187.	2.0	11
17	Hypermethylation of miR-145 promoter-mediated SOX9-CLDN8 pathway regulates intestinal mucosal barrier in Crohn's disease. EBioMedicine, 2022, 76, 103846.	6.1	6
18	Anti -TNFα agents in preventing the postoperative recurrence of Crohn's disease: Do they still play a role in the biological era?. Expert Opinion on Biological Therapy, 2021, 21, 1509-1524.	3.1	3

XIAOJUN ZHUANG

#	Article	IF	CITATIONS
19	Serum exosomal microRNA-144-3p: a promising biomarker for monitoring Crohn's disease. Gastroenterology Report, 2022, 10, goab056.	1.3	3
20	Development and validation of a nomogram to predict indolent course in patients with ulcerative colitis: a single-center retrospective study. Gastroenterology Report, 2022, 10, .	1.3	3
21	Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients. Frontiers in Medicine, 2020, 7, 557986.	2.6	1